Compare Stocks → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CALANASDAQ:EVLONASDAQ:KALVNYSE:LCINASDAQ:NEPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.02$0.03$0.01▼$0.50$120K-0.171,601 shs163 shsEVLOEvelo Biosciences$0.05$0.05$0.03▼$13.93$854K2.0446,928 shs32,383 shsKALVKalVista Pharmaceuticals$11.86+7.1%$13.56$6.83▼$16.88$500.37M0.9815,417 shs2.15 million shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsNEPTNeptune Wellness Solutions$0.43$0.19▼$28.00$906K2.19462,687 shs2.25 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-20.16%-20.32%-33.33%-50.00%EVLOEvelo Biosciences-13.00%-22.32%-27.50%-27.50%-98.95%KALVKalVista Pharmaceuticals-0.36%-9.48%-19.14%-8.36%+62.56%LCILannett0.00%0.00%0.00%0.00%-56.06%NEPTNeptune Wellness Solutions0.00%0.00%-45.95%-64.05%-98.95%Top Project Outperforms BTC in 2023… (Ad)According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals3.9497 of 5 stars3.51.00.04.51.82.50.6LCILannettN/AN/AN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness Solutions0.4717 of 5 stars0.03.00.00.03.20.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera BiosciencesN/AN/AN/AN/AEVLOEvelo Biosciences2.00HoldN/AN/AKALVKalVista Pharmaceuticals3.00Buy$26.33122.03% UpsideLCILannettN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/ACurrent Analyst RatingsLatest NEPT, LCI, EVLO, CALA, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/14/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $24.002/13/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $35.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.06EVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/A$2.10 per shareN/ALCILannett$340.58M0.00N/AN/A($23.34) per share0.00NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/A3/29/2024 (Estimated)EVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)KALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/AEVLOEvelo BiosciencesN/A0.480.48KALVKalVista PharmaceuticalsN/A5.445.44LCILannettN/A2.231.39NEPTNeptune Wellness SolutionsN/A0.230.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/AEVLOEvelo Biosciences0.31%KALVKalVista PharmaceuticalsN/ALCILannett40.28%NEPTNeptune Wellness Solutions14.44%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%EVLOEvelo Biosciences1.02%KALVKalVista Pharmaceuticals12.30%LCILannett13.12%NEPTNeptune Wellness Solutions5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableLCILannett81010.77 million9.35 millionOptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableNEPT, LCI, EVLO, CALA, and KALV HeadlinesSourceHeadlineWellness Wednesday – Focusing on Cardiovascular Healthnwahomepage.com - March 28 at 6:30 PMFood Encapsulation Market Industry Chain Information, Emerging Market Regions (2024-2032)taiwannews.com.tw - March 28 at 6:30 PMSNAPSHOT: The Bunker celebrates opening of newest location in Saratoga Springssaratogian.com - March 25 at 8:40 AMSNAPSHOT: Capital Region BOCES event will link students to employers and recruiterssaratogian.com - March 24 at 9:05 AMNeptune Wellness Solutions (NASDAQ:NEPT) Now Covered by Analysts at StockNews.comamericanbankingnews.com - March 23 at 2:16 AMKingdom Wellness & Dispensary opens new retail locationwestsidenewsny.com - March 18 at 12:39 PMWellness expo promotes better health within Black familiesksdk.com - March 17 at 8:17 PMRooted Wellness celebrates grand openinglowellsun.com - March 15 at 8:16 PMClinton to host Mayor's Wellness Program on Saturday, March 23newjerseyhills.com - March 15 at 3:15 PMYour Weekly Horoscopes: March 17 to 23, 2024purewow.com - March 15 at 12:13 AMHealthwise Wellness hosts clinic open housearkansasonline.com - March 13 at 7:38 AMSouthwell Center for Healing and Wellness to permanently closemsn.com - March 12 at 12:26 AMNeptune Software: 'Environmental Supply Chains - You Don't Need to Sacrifice Profitability to Act Sustainably'tmcnet.com - March 11 at 2:25 PMNeptune Wellness Solutions Inc.wsj.com - March 9 at 8:59 AMNeptune Wellness appoints Michael De Geus as interim president, CEOmsn.com - March 8 at 9:40 AMNeptune Appoints Interim President and CEO and Interim COOaccesswire.com - March 8 at 8:30 AMNeptune Wellness to be delisted from Nasdaqinvesting.com - March 8 at 12:42 AMTop Marijuana Stocks For Trading Today 2024marijuanastocks.com - March 6 at 9:06 AMNeptune Announces Decision of Nasdaq Hearings Panel To Delist Common Sharesaccesswire.com - March 6 at 8:30 AMNeptune Announces Michael Cammarata's Resignation Effective February 23, 2024accesswire.com - March 4 at 8:31 AM2 Top Marijuana Penny Stocks with High Momentum Before March 2024marijuanastocks.com - March 2 at 11:00 AMNeptune Puts Employees, Including Certain Key Executives, on Mandatory Unpaid Leave of Absence Beginning February 23, 2024accesswire.com - February 26 at 9:00 AMPisces Daily Horoscope Today, Feb 24, 2024 predicts embracing romancemsn.com - February 23 at 7:38 PMGEEKCO WELCOMES MICHEL TIMPERIO AS BOARD MEMBER AND GRANTS OPTIONS AND RSUfinance.yahoo.com - February 23 at 7:38 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCalithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.LannettNYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.